BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 37057835)

  • 1. Digital technology for early identification of exacerbations in people with cystic fibrosis.
    Wong CH; Smith S; Kansra S
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD014606. PubMed ID: 37057835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis.
    Pinto ACPN; Piva SR; Rocha A; Gomes-Neto M; Atallah ÁN; Saconato H; Trevisani VF
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD014605. PubMed ID: 37294546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis.
    Smith S; Calthorpe R; Herbert S; Smyth AR
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013733. PubMed ID: 36734528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis.
    Dawson S; Girling CJ; Cowap L; Clark-Carter D
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD013766. PubMed ID: 36989170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise versus airway clearance techniques for people with cystic fibrosis.
    Heinz KD; Walsh A; Southern KW; Johnstone Z; Regan KH
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013285. PubMed ID: 35731672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
    Southern KW; Solis-Moya A; Kurz D; Smith S
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics for people with cystic fibrosis.
    Coffey MJ; Garg M; Homaira N; Jaffe A; Ooi CY
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012949. PubMed ID: 31962375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
    Jain K; Wainwright CE; Smyth AR
    Cochrane Database Syst Rev; 2024 May; 5(5):CD009530. PubMed ID: 38700027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis.
    Jones M; Moffatt F; Harvey A; Ryan JM
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013610. PubMed ID: 37462324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
    Smith S; Rowbotham NJ
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD001021. PubMed ID: 36373968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Smith S; Rowbotham NJ; Charbek E
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD008319. PubMed ID: 35914011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Smith S; Rowbotham NJ; Charbek E
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD008319. PubMed ID: 30376155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics for exacerbations of asthma.
    Normansell R; Sayer B; Waterson S; Dennett EJ; Del Forno M; Dunleavy A
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002741. PubMed ID: 29938789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.
    Lo DK; Muhlebach MS; Smyth AR
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD009650. PubMed ID: 36511181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
    Janjua S; Mathioudakis AG; Fortescue R; Walker RA; Sharif S; Threapleton CJ; Dias S
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013198. PubMed ID: 33448349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.